Catalent, Inc. (NYSE:CTLT) Shares Sold by Boussard & Gavaudan Investment Management LLP

Boussard & Gavaudan Investment Management LLP decreased its holdings in Catalent, Inc. (NYSE:CTLT) by 21.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 302,336 shares of the company’s stock after selling 80,500 shares during the period. Catalent makes up approximately 1.7% of Boussard & Gavaudan Investment Management LLP’s investment portfolio, making the stock its 20th largest position. Boussard & Gavaudan Investment Management LLP’s holdings in Catalent were worth $18,261,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. O Shaughnessy Asset Management LLC acquired a new stake in shares of Catalent during the 1st quarter worth approximately $214,000. California State Teachers Retirement System increased its holdings in shares of Catalent by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 284,815 shares of the company’s stock worth $16,078,000 after buying an additional 1,149 shares during the last quarter. Swedbank AB acquired a new stake in shares of Catalent during the 1st quarter worth approximately $1,659,000. Redwood Grove Capital LLC increased its holdings in shares of Catalent by 23.0% during the 1st quarter. Redwood Grove Capital LLC now owns 308,156 shares of the company’s stock worth $17,395,000 after buying an additional 57,600 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its holdings in shares of Catalent by 2.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 31,445 shares of the company’s stock worth $1,763,000 after buying an additional 732 shares during the last quarter.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CTLT. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com cut shares of Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.40.

Catalent Stock Performance

Shares of CTLT stock opened at $61.00 on Thursday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.50. The stock has a market capitalization of $11.07 billion, a PE ratio of -26.99, a P/E/G ratio of 2.44 and a beta of 1.16. The firm has a 50 day moving average of $59.86 and a two-hundred day moving average of $58.41.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the business earned ($0.10) EPS. The business’s quarterly revenue was up 4.2% on a year-over-year basis. On average, research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.